Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + sintilimab + chemotherapy as neoadjuvant treatment for locally advanced thoracic esophageal squamous cell carcinoma
ChiCTR2400085302Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, sintilimab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Pathologic complete response. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tucidinostatsintilimabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400085302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085302.